Companies appear wary of developing drugs for gram-negative bacteria

02/28/2010 | New York Times (tiered subscription model), The

Treatments for gram-negative bacteria are rarely pursued by drugmakers because of the bacteria's drug resistance, according to The New York Times. The lack of drugs also stems from the reluctance of developers to invest in antibiotics. The few candidates against gram-negative infection have increased in value, and big companies are licensing them from Calixa Therapeutics and other smaller firms.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY